Hankyoreh on MSN1d
Appeals court upholds acquittal of Samsung’s Lee in 2015 merger caseLike the lower court, the appeals court did not accept prosecutors’ evidence of accounting fraud as admissible ...
A South Korean appeals court cleared Samsung Electronics Chair Lee Jae-yong Monday of stock manipulation and accounting fraud ...
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...
Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), which is Samsung Bioepis’s biosimilar to Soliris. Samsung Bioepis ...
On January 29, 2025, the Federal Circuit issued paired decisions addressing Samsung Bioepis’s (“SB”) and Formycon AG’s ...
THE CHOSUNILBO on MSN2d
Samsung Chairman Lee Jae-yong cleared of all charges in 2015 merger caseSamsung Electronics Chairman Lee Jae-yong was acquitted in an appellate trial on Feb. 3, clearing him of stock manipulation ...
(RTTNews) - Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis biosimilar to ...
INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly ...
Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback